Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: Interaction between intestinal and respiratory tracts and impact of nutritional exposures

mBio

Volumn 3, Issue 4, 2012, Pages

  Madan, J C ^a   Koestle, D C ^b   Stanton, B A ^b   Davidson, L ^c   Moulton, L A ^a   Housman, M L ^b   Moore, J H ^b   Guill, M F ^a   Morrison, H G ^d   Sogin, M L ^d   Hampton, T H ^b   Karagas, M R ^b   Palumbo, P E ^b   Foster, J A ^e   Hibberd, P L ^f   O'Toole, G A ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MARINE BIOLOGICAL LABORATORY   (United States)

^e UNIVERSITY OF IDAHO   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA 16S;

ARTICLE; ARTIFICIAL MILK; BACTERIAL COLONIZATION; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM EXAMINATION; BACTEROIDACEAE; BACTEROIDES; BIFIDOBACTERIUM; BLAUTIA; BREAST FEEDING; CHILD DEVELOPMENT; CHILD NUTRITION; CLINICAL ARTICLE; CLOSTRIDIUM; CYSTIC FIBROSIS; EXPOSURE; GENE CLUSTER; GRAM POSITIVE BACTERIUM; HAEMOPHILUS; HUMAN; INTESTINE FLORA; MICROBIAL COMMUNITY; MICROBIAL DIVERSITY; MICROBIOME; NEISSERIA; NEWBORN; NUTRITIONAL ASSESSMENT; PARABACTEROIDES; PREVOTELLA; PRIORITY JOURNAL; RNA SEQUENCE; SPECIES COMPOSITION; STREPTOCOCCUS; VEILLONELLA;

BACTERIA (MICROORGANISMS); STREPTOCOCCUS; VEILLONELLA;

EID: 84865726240     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00251-12     Document Type: Article

References (55)

1. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. 2002. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr. Pulmonol. 34:91-100.
2. Bronstein MN, et al. 1992. Pancreatic insufficiency, growth, and nutrition in infants identified by newborn screening as having cystic fibrosis. J. Pediatr. 120:533-540.
3. Cox MJ, et al. 2010. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS One 5:e11044. http://dx.doi.org/10.1371/journal.pone.0011044.
4. Rosenecker J. 2000. Relations between the frequency of the deltaF508 mutation and the course of pulmonary disease in cystic fibrosis patients infected with Pseudomonas aeruginosa. Eur. J. Med. Res. 5:356-359.
5. McKone EF, Emerson SS, Edwards KL, Aitken ML. 2003. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 361:1671-1676.
6. Polizzi A, et al. 2005. Phenotypic expression of genotype-phenotype correlation in cystic fibrosis patients carrying the 852del22 mutation. Am. J. Med. Genet. A 132:434-440.
7. Rosenfeld M, et al. 2010. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr. Pulmonol. 45:934-944.
8. Schaedel C, et al. 2002. Predictors of deterioration of lung function in cystic fibrosis. Pediatr. Pulmonol. 33:483-491.
9. Sagel SD, et al. 2009. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J. Pediatr. 154:183-188.
10. Green DM, et al. 2010. Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients. Respir. Res. 11:140.
11. Collaco JM, Blackman SM, McGready J, Naughton KM, Cutting GR. 2010. Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. J. Pediatr. 157: 802-807.
12. Hudson VL, Wielinski CL, Regelmann WE. 1993. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. J. Pediatr. 122:854-860.
13. Rosenfeld M, et al. 2001. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr. Pulmonol. 32: 356-366.
14. Stoltz DA, et al. 2010. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci. Transl. Med. 2:29ra31.
15. Sordé R, Pahissa A, Rello J. 2011. Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis. Infect. Drug Resist. 4:31-41.
16. Stutman HR, Lieberman JM, Nussbaum E, Marks MI. 2002. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J. Pediatr. 140:299-305.
17. Frederiksen B, Koch C, Høiby N. 1997. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23:330-335.
18. Norkina O, Burnett TG, De Lisle RC. 2004. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect. Immun. 72:6040-6049.
19. Rosenfeld M, et al. 1999. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis. Pediatr. Pulmonol. 28: 321-328.
20. Klepac-Ceraj V, et al. 2010. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa. Environ. Microbiol. 12:1293-1303.
21. Simpson E. 1949. Measurement of diversity. Nature 163:688.
22. Houseman EA, et al. 2008. Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributions. BMC Bioinformatics 9:365.
23. Filkins LM, et al 29 June 2012. The prevalence of streptococci and increased polymicrobial diversity associated with cystic fibrosis patient stability. J. Bacteriol. http://dx.doi.org/10.1128/JB.00566-12.
24. Rogers GB, et al. 2010. Comparing the microbiota of the cystic fibrosis lung and human gut. Gut Microbes 1:85-93.
25. Rogers GB, et al. 2009. Studying bacteria in respiratory specimens by using conventional and molecular microbiological approaches. BMC Pulm. Med. 9:14.
26. Tunney MM, et al. 2008. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 177:995-1001.
27. Rogers GB, Skelton S, Serisier DJ, van der Gast CJ, Bruce KD. 2010. Determining cystic fibrosis-affected lung microbiology: comparison of spontaneous and serially induced sputum samples by use of terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 48: 78-86.
28. Stressmann FA, et al Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience. Thorax, in press.
29. Sibley CD, et al. 2011. Culture enriched molecular profiling of the cystic fibrosis airway microbiome. PLoS One 6:e22702. http://dx.doi.org/10.1371/journal.pone.0022702.
30. Cephas KD, et al. 2011. Comparative analysis of salivary bacterial microbiome diversity in edentulous infants and their mothers or primary care givers using pyrosequencing. PLoS One 6:e23503. http://dx.doi.org/10.1371/journal.pone.0023503.
31. Rogers GB, et al. 2003. Bacterial diversity in cases of lung infection in cystic fibrosis patients: 16S ribosomal DNA (rDNA) length heterogeneity PCR and 16S rDNA terminal restriction fragment length polymorphism profiling. J. Clin. Microbiol. 41:3548-3558.
32. Favier CF, Vaughan EE, De Vos WM, Akkermans AD. 2002. Molecular monitoring of succession of bacterial communities in human neonates. Appl. Environ. Microbiol. 68:219-226.
33. Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. 2007. Development of the human infant intestinal microbiota. PLoS Biol. 5:e177. http://dx.doi.org/10.1371/journal.pbio.0050177.
34. Yatsunenko T, et al. 2012. Human gut microbiome viewed across age and geography. Nature 486:222-227.
35. Costello EK, et al. 2009. Bacterial community variation in human body habitats across space and time. Science 326:1694-1697.
36. Zemanick ET, Sagel SD, Harris JK. 2011. The airway microbiome in cystic fibrosis and implications for treatment. Curr. Opin. Pediatr. 23: 319-324.
37. Delhaes L, et al. 2012. The airway microbiota in cystic fibrosis: a complex fungal and bacterial community-implications for therapeutic management. PLoS One 7:e36313. http://dx.doi.org/10.1371/journal.pone.0036313.
38. Zhao J, et al. 2012. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc. Natl. Acad. Sci. U. S. A. 109:5809-5814.
39. Huang YJ, Lynch SV. 2011. The emerging relationship between the airway microbiota and chronic respiratory disease: clinical implications. Expert. Rev. Respir. Med. 5:809-821.
40. Bruzzese E, et al. 2007. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin. Nutr. 26:322-328.
41. Youn HN, et al. 2012. Intranasal administration of live Lactobacillus species facilitates protection against influenza virus infection in mice. Antiviral Res. 93:138-143.
42. Tanaka A, et al. 2011. Lactobacillus pentosus strain b240 suppresses pneumonia induced by Streptococcus pneumoniae in mice. Lett. Appl. Microbiol. 53:35-43.
43. Thomas DJ, et al. 2011. Lactobacillus rhamnosus HN001 attenuates allergy development in a pig model. PLoS One 6:e16577. http://dx.doi.org/10.1371/journal.pone.0016577.
44. Turroni F, et al. 2012. Diversity of bifidobacteria within the infant gut microbiota. PLoS One 7:e36957. http://dx.doi.org/10.1371/journal.pone.0036957.
45. Biesbroek G, et al. 2012. Deep sequencing analyses of low density microbial communities: working at the boundary of accurate microbiota detection. PLoS One 7:e32942. http://dx.doi.org/10.1371/journal.pone.0032942.
46. Sogin ML. 2009. Characterizing microbial population structures through massively parallel sequencing, p 19-34. In Epstein SS (ed), Uncultivated Microorganisms. Springer, New York, NY.
47. Huse SM, Huber JA, Morrison HG, Sogin ML, Welch DM. 2007. Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol. 8:R143. http://dx.doi.org/10.1186/gb-2007-8-7-r143.
48. Huse SM, et al. 2008. Exploring microbial diversity and taxonomy using SSU rRNA hypervariable tag sequencing. PLoS Genet. 4:e1000255. http://dx.doi.org/10.1371/journal.pgen.1000255.
49. Pruesse E, et al. 2007. SILVA: a comprehensive online resource for quality checked and aligned ribosomal RNA sequence data compatible with ARB. Nucleic Acids Res. 35:7188-7196.
50. Hill M. 1973. Diversity and evenness: a unifying notation and its consequences. Ecology 54:427-432.
51. Christensen BC, et al. 2011. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J. Natl. Cancer Inst. 103:143-153.
52. Marsit CJ, et al. 2011. DNA methylation array analysis identifies profiles of blood-derived DNA methylation associated with bladder cancer. J. Clin. Oncol. 29:1133-1139.
53. Christensen BC, et al. 2009. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res. 69:227-234.
54. Potter DM. 2005. A permutation test for inference in logistic regression with small- and moderate-sized data sets. Stat. Med. 24:693-708.
55. Rocke D. 1993. On the beta transformation family. Technometrics 35: 72-81.